First-in-human therapy with Treg produced from thymic tissue (thyTreg) in a heart transplant infant.
J Exp Med
; 220(12)2023 12 04.
Article
in En
| MEDLINE
| ID: mdl-37906166
ABSTRACT
Due to their suppressive capacity, regulatory T cells (Tregs) have attracted growing interest as an adoptive cellular therapy for the prevention of allograft rejection, but limited Treg recovery and lower quality of adult-derived Tregs could represent an obstacle to success. To address this challenge, we developed a new approach that provides large quantities of Tregs with high purity and excellent features, sourced from thymic tissue routinely removed during pediatric cardiac surgeries (thyTregs). We report on a 2-year follow-up of the first patient treated worldwide with thyTregs, included in a phase I/II clinical trial evaluating the administration of autologous thyTreg in infants undergoing heart transplantation. In addition to observing no adverse effects that could be attributed to thyTreg administration, we report that the Treg frequency in the periphery was preserved during the 2-year follow-up period. These initial results are consistent with the trial objective, which is to confirm safety of the autologous thyTreg administration and its capacity to restore the Treg pool.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Heart Transplantation
/
T-Lymphocytes, Regulatory
Limits:
Adult
/
Humans
/
Infant
Language:
En
Journal:
J Exp Med
Year:
2023
Document type:
Article
Affiliation country:
Spain